The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Peptide Based Metabolic Disorders Therapeutics Market During 2026–2030?
The market for peptide based metabolic disorders therapeutics has witnessed rapid expansion over recent years. It is anticipated to increase from $34.1 billion in 2025 to $39.05 billion in 2026, registering a compound annual growth rate (CAGR) of 14.5%. Historically, this market’s expansion can be attributed to the rising prevalence of type 2 diabetes, the early achievements of liraglutide and exenatide therapies, increasing clinical validation of peptide drugs, escalating obesity rates in developed economies, and a better understanding of metabolic pathways.
The market for peptide-based metabolic disorder therapeutics is projected to experience swift expansion over the coming years. This market is forecast to reach $63.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. Factors contributing to this growth during the forecast period include the increasing global prevalence of obesity, the wider embrace of semaglutide and advanced peptides, a surge in investment directed towards metabolic disorder drug development, a rising need for enduring weight management options, and innovations in peptide drug delivery mechanisms. Key trends anticipated for the forecast period encompass a greater acceptance of GLP-1 receptor agonist treatments, an amplified emphasis on peptide-centric obesity management strategies, the broadening availability of long-acting injectable peptide formulations, an uptick in the application of combined peptide therapies, and an increasing desire for metabolic treatments that are user-friendly for patients.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Which Major Factors Are Driving The Expansion Of The Peptide Based Metabolic Disorders Therapeutics Market?
The increasing occurrence of obesity is anticipated to boost the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity is defined as a medical condition where excessive body fat accumulates, leading to health hazards. The growing incidence of obesity stems from inactive lifestyles, poor eating habits, inherited predispositions, and environmental factors that encourage high-calorie diets and lack of physical activity. Therapeutics for metabolic disorders utilizing peptides work to address conditions like obesity by employing peptides to modulate metabolic processes, enhance insulin responsiveness, and regulate hunger, consequently improving patient well-being and mitigating enduring health risks linked to these chronic ailments. As an illustration, data from December 2024, provided by the Office for Health Improvement and Disparities, a UK-based government department, indicated that the percentage of women diagnosed with obesity in early pregnancy rose from 25.4% between 2022 and 2023 to 26.2% between 2023 and 2024. Consequently, the escalating rates of obesity are fueling the demand within the peptide-based metabolic disorder therapeutics market.
How Are The Various Segments Of The Peptide Based Metabolic Disorders Therapeutics Market Categorized?
The peptide based metabolic disorders therapeutics market covered in this report is segmented –
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
What Trends Are Affecting The Expansion Of The Peptide Based Metabolic Disorders Therapeutics Market?
Leading companies in the peptide-based metabolic disorders therapeutics market are developing innovative peptide-based treatments, such as anti-diabetic biosimilars, to address unmet medical needs and expand patient treatment options. Peptide-based anti-diabetic biosimilars refer to therapeutic drugs that mimic existing peptide-based therapies for diabetes, offering comparable efficacy and safety profiles to established medications while potentially lowering treatment costs through competitive pricing strategies. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit, a biosimilar version of the popular anti-diabetic drug Liraglutide in India. It belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This class of drugs mimics the action of the naturally occurring GLP-1 hormone, which is crucial in regulating blood sugar levels. This biosimilar has undergone clinical trials demonstrating its effectiveness in lowering glycemic parameters, promoting weight reduction, and enhancing cardiovascular safety. These are crucial benefits for managing diabetes and associated conditions such as obesity and cardiovascular diseases.
Which Major Firms Influence Developments In The Peptide Based Metabolic Disorders Therapeutics Market?
Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc
Read the full peptide based metabolic disorders therapeutics market report here:
Which Region Currently Holds The Largest Share Of The Peptide Based Metabolic Disorders Therapeutics Market?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Peptide Based Metabolic Disorders Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp
Browse Through More Reports Similar to the Global Peptide Based Metabolic Disorders Therapeutics Market 2026, By The Business Research Company
Peptide Based Metabolic Disorders Therapeutics Market Report 2026
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model